After countries such as the United States and Japan, the European Union may also approve Redciewe for the treatment of new coronary pneumonia. Guido Rasi, head of the European Medicines Agency (EMA), told an EU parliamentary hearing on the same day that the agency may initially approve the antiviral drug Remdesivir, developed by Gilead, to treat the new coronary pneumonia. “Redsieway may get a conditional listing permit in the near future, ” Mr. Lacey said. “
The European Medicines Agency has reportedly recommended a “sympathetic dosing” of redsiewe in patients with new coronary pneumonia, i.e. the use of unapproved drugs.
In addition to Redcie, monoclonal antibody-based treatments may also be used in the near future, Lacey said. It is reported that the treatment can be “moderated” to the new coronavirus.
Gilead developed Ridsiewe’s original plan for diseases such as Ebola haemorrhagic fever and MERS. According to earlier reports, the U.S. Food and Drug Administration (FDA) on March 23 local time has approved Redsiewe’s “orphan drug” certification, May 1 issued an emergency use authorization, allowing the treatment of patients with severe coronary pneumonia “emergency use” of redsywe. Japan also “exceptionally approved” redsiewe on May 7 to treat new coronary pneumonia. Clinical trials have also been conducted to treat new coronary pneumonia with Redcivir.